LIVE RECORDING OF DAVID COOK’S ‘IDOL’ PERFORMANCE WILL BE SOLD ON iTUNES TO RAISE FUNDS FOR CHARITY
All Proceeds From Sale of Live Version of ‘Permanent’ Will Be Donated To D.C.-Based Accelerate Brain Cancer Cure
Exactly one year after winning the seventh season of “American Idol,” David Cook returns to the most popular television series in America on Wednesday night to perform “Permanent,” — a song he wrote with Chantal Kreviazuk and Raine Maida. The studio version of “Permanent” appears on his platinum-selling debut album for 19 Recordings/RCA Records, “David Cook.” The live recording will be available for purchase on iTunes immediately after the live broadcast. 100 percent of the proceeds will go to Accelerate Brain Cancer Cure (ABC2), a Washington, D.C.-based organization dedicated to finding a cure for brain cancer.
Earlier this month, Cook raised money and awareness for ABC2 by running in the organization’s 5K “Race for Hope” in the District of Columbia. Now, the live recording of “Permanent” will be available as a charity single on iTunes for one month, raising more money to benefit ABC2. The organization uses an entrepreneurial venture philanthropy approach to bring more treatments to patients sooner by stimulating new research and accelerating the development of new therapies for brain cancer. ABC2 looks forward to the day when all patients who are diagnosed with brain cancer can be told they have a manageable disease.
ABC2 provides researchers with the pivotal support they need to make critical breakthroughs. The organization funds novel translational research aimed at finding the fastest possible route to a cure. ABC2’s partners range from medical research centers to early-stage biotechnology companies to large multi-national pharmaceutical companies. Since brain cancer affects a relatively small portion of the population, ABC2 recognizes the importance of investing in the early stages of the most novel sectors of the discovery and development pipeline, in order to “buy down the risk” for its partners and speed progress of innovative new treatments to the clinic.